Who are TURCOVAC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): The Pfizer mRNA-based BNT162b2 vaccine, Casirivimab and Imdevimab Drug Combination, mRNA-1273, BioNTech - Pfizer COVID-19 vaccine, mRNA-1273 Variant-containing Formulation, COVID-19 mRNA vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/turcovac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

TURCOVAC — Competitive Intelligence Brief

TURCOVAC (TURCOVAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

phase 3 vaccine SARS-CoV-2 spike protein Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

TURCOVAC (TURCOVAC) — Health Institutes of Turkey. TURCOVAC is a vaccine that works by stimulating the body's immune system to produce antibodies against the SARS-CoV-2 virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TURCOVAC TARGET	TURCOVAC	Health Institutes of Turkey	phase 3	vaccine	SARS-CoV-2 spike protein
The Pfizer mRNA-based BNT162b2 vaccine	The Pfizer mRNA-based BNT162b2 vaccine	dafna yahav	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
BioNTech - Pfizer COVID-19 vaccine	BioNTech - Pfizer COVID-19 vaccine	University of Birmingham	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TURCOVAC — Competitive Intelligence Brief. https://druglandscape.com/ci/turcovac. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab